Post on 25-Jan-2021
Revised: 2017/11/29 1
CURRICULUM VITAE (Revised 2016-11-09)
I. BIOGRAPHICAL DATA
Name: Philip A. Barber
Date of Birth: July 6, 1968
Address: Department of Clinical Neurosciences
University of Calgary
Calgary, Alberta
CANADA
Telephone: 403 944 4399
Fax: 403 270 8928
Citizenship: British
Canadian
Present rank: Associate Professor
Department: Clinical Neurosciences, Radiology
Faculty: Cumming School of Medicine
Institution: University of Calgary
II. ACADEMIC RECORD
Final degree: MB ChB
Date completed: 1991
Specialty: Neurology
Institution of Neurology training: Department of Clinical Neuroscience, Manchester
University, United Kingdom
i) Undergraduate: MB ChB 1986-1991 Sheffield University Medical School ii) Special professional:
MRCP (UK), March 1995
Certificate of Completion of Specialist Training (CCST) in Neurology, Oct 2001
Fellow of the Royal College of Physicians Canada, FRCPC (Neurology), May 2005
Fellow of the Royal College of Physicians Edinburgh, FRCP Edin, July 2006 iii) Licensure: Full registration, Royal College of Surgeons and Physicians of Alberta.
General Medical Council Specialist Register
iv) Doctorate of Medicine (MD), University of Sheffield, UK, July 2005
Revised: 2017/11/29 2
III. AWARDS AND DISTINCTIONS
The Old Cestrian Prize 1986
Swann Morten Medical Student Fellowship Award 1990
North of England Neurological Association Travel Award 1998
Glaxo Wellcome Fellowship Award 1998
Canadian Institute of Health Research Postdoctoral Fellowship 2001
Heart and Stroke Foundation of Canada Postdoctoral Fellowship 2001
Alberta Foundation for Medical Research Postdoctoral Fellowship 2001
Canadian Stroke Network Award for the best Postdoctoral Fellowship Application March 2001
EH Burrows Scientific Prize. Annual Scientific Meeting of the British Society of
Neuroradiologists, Guildhall, Winchester, 11-12 October 2002
Alberta Heritage Foundation of Medical Research Clinical Investigator 2005-2008
Alberta Heritage Foundation of Medical Research Prize 2005-2011
Canadian Institute of Health Research New Investigator 2005-2010 (declined)
Heart Stroke Foundation of Canada New Investigator 2005-2010
Henry JM Barnett Research Scholarship Award 2005/2006
University of Calgary Young Innovator Award 2005
2015 ASTech Award Winner: Societal Impact Calgary Stroke Program (Nov 2015)
2016 President’s Excellence Award for Outstanding Achievement in Research - ESCAPE Trial
Team
IV. ACADEMIC/CLINICAL APPOINTMENTS
Present
Associate Professor, Department of Clinical Neurosciences, University of Calgary, 3330 Hospital
Drive NW, Calgary T2N 4N1, CANADA.
Adjunct Professor, Associate Professor, Department of Radiology, University of Calgary,
Cumming School of Medicine (effective July 2009)
Joint Appointment, Associate Professor – Department of Community Health Sciences
(May 1, 2017-June 30, 2019)
Consultant Neurologist, Foothills Hospital, 1403-29th ST NW, Calgary, AB, CANADA
Hospital Training & Positions
August 1991- January 1992: House Officer in General Surgery and Orthopedics, Barnsley
District General Hospital. Mr. B G Way & Mr. B Bhadeshwar
February 1992 April 1992: House Officer in General Medicine and Hepatology Royal
Hallamshire Hospital Sheffield. Dr D Greaves, Dr N D S Bax & Professor D Triger
Revised: 2017/11/29 3
May 1992 July 1992: House Officer in Neurology Royal Hallamshire Hospital Sheffield.
Dr G A B Davies-Jones & Professor J H Sagar
August 1992- January 1993: Senior House Officer, General Medicine & Care of the Elderly St
Georges Hospital Lincoln. Dr D M Stokoe
February 1993- July 1993: Senior House Officer in General Medicine and Hematology Lincoln
County Hospital Lincoln. Dr D R Prangnell & Dr M I Adelman & Professor J. Walls
August 1993- January 1994: Senior House Officer in General Medicine & Respiratory Diseases
Northern General Hospital Sheffield. Dr P B Anderson
February 1994- July 1994: Senior House Officer in Accident & Emergency Medicine, Northern
General Hospital Sheffield. Mr. J Wardrope & Dr F P Morris
August 1994- January 1995: Senior House Officer in Cardiology, Northern General Hospital
Sheffield. Dr S Campbell
February 1995-1 August 1995: Senior House Officer in Clinical Neurology Royal Hallamshire
Hospital Sheffield. Dr G S Venables & Dr G A B Davies-Jones
August 1995-December 1995: Locum Registrar in Geriatrics and General Medicine Royal
Hallamshire Hospital Sheffield. Dr P Lawson, Professor L Ramsay
December 1995 Locum Registrar in Neurology Leeds General Infirmary. Drs. Parsons & Spokes
Specialty Training
1st January 1996- 30th April 1996: Registrar in Clinical Neurology and Neurophysiology. North
Manchester General Hospital. Dr G M Yuill, Dr D I Shepherd & Dr J Smaje.
1st May 1996- 31st December 1996: Registrar in Clinical Neurology, Salford Royal Hospital Trust
Dr A C Young & Dr P N Cooper
1st Jan 1997 –31st December 1997: Specialist Registrar in Clinical Neurology and
Neurophysiology, Manchester Royal Infirmary Professor D Neary & Dr W Schady
1st January 1998- 31st September 1998: Specialist Registrar in Neurology and Neurophysiology,
Salford Royal Hospital Trust. Dr G Yuill & Dr D Shepherd
1st October 1998- 31st September 2001: Clinical Neurology Fellow, Foothills Medical Centre,
Calgary, Canada. Dr AM Buchan
October 1st 2001- June 30th 2003 Postdoctoral Fellow, and Visiting Scientist, National Research
Council, Institute of Biodiagnostics (West), Room 153 3330 Hospital Drive NW, Calgary T2N
4N1, CANADA. Supervisor: Dr Alastair Buchan
Revised: 2017/11/29 4
July 1st 2003- March 30th 2009 Assistant Professor, Department of Clinical Neurosciences,
University of Calgary and Visiting Scientist, National Research Council, Institute of
Biodiagnostics (West), Room 153 3330 Hospital Drive NW, Calgary T2N 4N1, CANADA.
April 1st 2009-July 31st 2011 Associate Professor, Department of Clinical Neurosciences,
University of Calgary and Visiting Scientist, National Research Council, Institute of
Biodiagnostics (West), Room 153 3330 Hospital Drive NW, Calgary T2N 4N1, CANADA.
August 1st 2011-July 31st 2011 Honorary Senior Research Associate, Dementia Research Centre,
National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG
V. EDUCATIONAL ACTIVITIES
i. Undergraduate Undergraduate clinical bedside and small group teaching 1994-1996 University of
Sheffield, UK
Undergraduate weekly clinical bedside and small group teaching 1996-1998 University of
Manchester, UK
Neurological Syndrome Classification. University of Manchester May 1997
Neuroscience Course clinical bedside teaching University of Calgary, 1999-2004 (6 week
period)
Ischemic Stroke: symptoms and signs. Neuroscience Undergraduate Course August 1999
Neuroscience Clinical Small Group Teaching, August-September 2000-2008
Stroke Seminar: ‘Stroke Symptoms and Signs’, September 2000
Stroke Seminar: ‘Pathophysiology of Ischemic and Hemorrhagic Stroke’, Neuroscience
Course September 2001-2008
Undergraduate Stroke Course Modulator 2010 to present
ii. Graduate (course and student supervision) MRCP part II teaching 1995-1998, University of Manchester and Sheffield, UK
APSAC diploma March and September 1997 University of Manchester, UK
Secondary Stroke Prevention. University of Calgary Therapeutics Course March 1999
Resident Stroke Rounds. Monthly teaching September-June 1999-2001
Neurology Resident Seminar: The Biochemistry of Ischemic Stroke November 2002-
2008
Resident stroke service in patient teaching: 2000-2009
TORCH PROGRAM, University of Calgary 2005-present
Animal Stroke Models and Neurotherapeutics
Clinical stroke treatments and thrombolysis
Revised: 2017/11/29 5
Summer Student Supervision:
1. Nitin Chauhan 2003 2. Hisham Assam 2005 and 2006 3. Jessica Hung King Sang (AHFMR Studentship 2007 and 2008) 4. Zahid Sunderani (AHFMR Studentship 2007) 5. Royce Henning (AHFMR Studentship 2008) 6. Brian Cechmaniek (AHFMR Studentship 2010) 7. Brian Cechmaniek (PURE Studentship 2011) 8. Ajay Mahajan 2013 (Volunteer Position) 9. Mohammad (Amlish) Munir 2013 (CIHR QE2 Scholarship Award) 10. Ajay Mahajan 2014 (CSN Studentship) 11. Samantha Hall 2014 (PURE Studentship) 12. Stephen Campeau 2015 (O’Brien Centre Summer Studentship Award) to Apr 2016 13. Ajay Mahajan 2015 (AI-HS Summer Studentship Award); 2016 Mar/Apr (Research Block) 14. Jacob Ursenbach 2016 (PREVENT Study) 15. Naomi-Rose A. Dutta 2016 (PREVENT Study) 16. Moiz Hafeez 2016 (QuICR Scholarship Award) 17. Gavin Lau 2017 May-Aug (QuICR Scholarship Award) 18. Meaghan Reid May –Aug 2017 (PREVENT Study)
Supervisory: Students & Fellows
Clinical Stroke Fellows
1. James Kennedy (Feb01-Mar05) · Faculty Oxford University, England starting 2006
2. Anna Tomanek (Jul01-Jun03) · AIMG Program Family Medicine 2004 and now practicing as family physician in Calgary
3. Jessica Simon (Jul01-Dec04) · Medicine resident in Calgary, starting 2004
4. Shelagh Coutts (Aug2001-Jun2004) · Faculty, University of Calgary, starting 2006
5. Vanessa Palumbo (Dec02-Jun05) · Faculty, Florence, Italy, starting 2006
6. Alexis Gagnon (Jul03-Jun04)
· Faculty, University of Quebec, starting 2005
7. Nicolas Weir (Jan04-Dec05)
· Faculty, University of Calgary, starting 2006-2009; Consultant Neurologist Southampton
General Hospital)
8. Chandresekaran Sivakumar (May04-May05)
· Faculty, University of Calgary, starting 2006
9. Jayanta Roy (Jul04-Mar05)
· Faculty, Kolkata, India, starting 2006
10. Suresh Subramaniam (Jul2004-Mar2006)
· Neurology resident in Calgary starting 2006
11. Jean-Martin Boulanger (Aug04-Jul05)
· Faculty, University of Sherbrooke, starting 2005
Revised: 2017/11/29 6
12. Imanuel Dzialowski (Feb05-Jan06)
· Completing Neurology residency, Dresden, Germany, starting 2006
13. Sylaja Pillai (Jul05-Dec06)
14. Volker Peutz (Mar06- Dec07)
15. Mohamad Awastami (Jul06-)
16. Ali Al-Khatami (Aug06-Jul07)
17. Albert Jin (Aug06-Jul08) Faculty Queens’s University, Kingston, ON
18. Young Bin Choi (Sep06-Jun07)
19. Farosh Khan (Jan 07-)
20. Cynthia Herrera (Feb 07-March 08)
21. Alex Poppe (Aug 2007-8)
22 Talip Asil (Feb 2008-9)
23 Pablo Garcia (Mar 2008-Jul 2009)
24 Nan Shoba (Jul 2008-Nov 2010)
25. Bejoy Menon (Nov 2008-May 2011) Faculty, University of Calgary
26. Rohit Bhatia (Jan 2009-) Associate Professor, New Delhi
27. Deon Fung (Jul 09-2011)
28. Francois Moreau (Jul 09-2011) Faculty, Sherbrooke Hospital, QC
29. Nagar Asdagi (Jul 09-2011) Faculty, Vancouver General
30. Anurag Trivedi (Feb 2013-Jan 2015) Stroke Fellow, University of Victoria, BC
31. Veronique Dubuc (Jul 2013-Jun 2014) Staff Neurologist, Sacre Coeur Hospital, Montreal,
QC
32. Philip Choi (Jul 2013-Nov 2014) Staff Neurologist, Box Hill Hospital, Melbourne, AU
33. Evgenia Klourfeld (Jul 2013-Jun 2015) Attending Neurologist, Foothills Medical Centre, AB
34. Dilip Singh (Aug 2013-) Clinical Instructor, Ohio State University Wexner Medical Center
35. Tapuwa Musuka (Aug 2013-Jun 2014) Staff Neurologist, Fiona Stanley Hospital, Perth, AU
36. Ramana Appireddy (Jan 2014-) Stroke Fellow, University of Calgary
37. Sarah Blayney (Mar 2014-Feb 2015) Consultant Physician in Stroke & Geriatric Medicine,
Cheltenham & Gloucester NHS Foundation Trust
38. Unuigboje Imoukhuede (Jul 2014-Jun 2015) Attending Neurologist, Red Deer Hospital
Centre, Red Deer, AB
39. Davar Niknesham (Jul 2014-Jun 2015) Staff Neurologist, St. Catherine’s Site, Niagara
Health System, St. Catherine’s, ON
40. Amy Yu (Jul 2014-Jun 2106) Stroke Fellow, University of Calgary
41. Fahad S. Al-Ajlan (Sept 2014-Jun 2015) Research Fellow, Calgary Stroke Program
42. Ruba Baamer (Jan-Mar 2015) Stroke Fellow, Calgary Stroke Program
43. Charlotte Zerna (Jan 2015-Dec 2016) Stroke Fellow, Calgary Stroke Program
44. Janka Hegedus (Jul 2015- Jun 2016) Stroke Fellow, Calgary Stroke Program
45. Prasanna Eswaradass (Jul 2015-ongoing) Stroke Fellow, Calgary Stroke Program
46. Carol Tham (Aug 2015-Jul 2016) Stroke Fellow, Calgary Stroke Program
47. Sadanand Dey (Dec 2015-Nov 2016) Stroke Fellow, Calgary Stroke Program
48. James Evans (Feb 2016-Jan 2017) Stroke Fellow, Calgary Stroke Program
49. Amith Sitaram (Mar 2016-ongoing) Stroke Fellow, Calgary Stroke Program
50. Ericka Teleg (Apr 2016-ongoing) Stroke Fellow, Calgary Stroke Program
51. Brett Graham (Jul 2016-ongoing) Stroke Fellow, Calgary Stroke Program
52. Stephen Van Gaal (Jul 2016-ongoing) Stroke Fellow, Calgary Stroke Program
Revised: 2017/11/29 7
53. Aimen Moussaddy (Sept 2016-ongoing) Stroke Fellow, Calgary Stroke Program
54. Debabrata Chakraborty (Nov 2016-ongoing) Stroke Fellow, Calgary Stroke Program
55. Nicolas Maraj (Jan 2017-ongoing) Stroke Fellow, Calgary Stroke Program
56. Abdulaziz Sulaiman Al Sultan (Jul 2017-ongoing)
57. Shuo Chen (Jul 2017-ongoing)
58. Andrew Lockey (Jul 2017-ongoing)
59. Ravinder Singh (Jul 2017-ongoing)
Post-Doctoral Fellows
68. Albert Jin 2006-2008
69. Jaspreet Kaur 2006-2009
70. Chris d’Esterre May 2014-
71. Kelvin Au (Postgraduate) 2015 Jan-
72. Rani Gupta Sah 2015 Jan-2018 Apr
73. Charlotte Zerna 2015 Jan-2016 Dec
74. Noreen Kamal 2016 Jan-2016 Sept (Co-Supervisor)
75. Amith Sitaram 2016 Mar-ongoing
Graduate Students – Department of Clinical Neurosciences (Primary Supervisor)
76. Lisa Hoyte 2002-2003
77. Pia Crone Christensen 2007-2008
78. Nabeela Nathoo 2009-2010
79. Mohammad (Amlish) Munir 2013 Dec-2015 Dec (MSc Student)
80. Sana Tariq 2016 Jan-2017 May (Master’s MSc Candidate)
81. Moiz Hafeez 2016 Sept-2017 May (Master’s MSc Student)
Accepted to UofC MD Program Fall 2018 (under a new supervisor)
82. Samaneh Nobakht 2016 Sept- (PhD, Neurosciences Program)
83. Meaghan Reid 2017 Sept-(MSc Graduate) Master of Science, Fall 2018 (Co-Supervisor)
Undergraduate Thesis Candidates (Primary Supervisor)
Brian Cechmanek 2013
Kathy Le April 2014
Stephen Campeau 2015 Sept-2016 Aug (Honour’s)
Gavin Lau Sept 2017 to May 2018 (Honour’s)
Revised: 2017/11/29 8
Research Associate
Zonghang Zhao 2006-present
Limei Wang 2009-2011
Research Assistant
Sana Tariq 2014 Sept-2015 Dec (Graduate MSc, Neuroscience Program;
PREVENT/REPERFUSE)
University of Calgary MD Program
Robert Kosior - 2012-2014 (Affiliate member of the Leaders in Medicine Program)
Robert Kosior - 2014-2015 (440 Candidate Program, Mentorship Program)
Omar Danji - 2015-2016 Jun (440 Candidate Program, Mentorship Program)
iii. Continuing Medical Education
March 1991 - Radiation Protection Course, Sheffield UK
March 1995 - Advanced Cardiac Life Support, Sheffield UK
May 1997 - Medical Statistics, Sheffield Statistics Unit, UK
June 1997 - Botulinum Toxin Workshop, Manchester Royal Eye Hospital UK
October 1997 - International League Against Epilepsy, Specialist Registrar Training Course, Oxford UK
November 1997- Edinburgh Stroke Course, Edinburgh UK
March 1998 - Advanced Neurology Course, Edinburgh UK
October 1998 - Acute Stroke Symposium, Calgary, Ca
January 1999 - Neuroradiology Conference, Banff, Canada.
February 1999 - American Heart (stroke) Association Meeting, Nashville, United States.
March 1999 - Association of British Neurologists, Parkinson’s Disease Symposium. Southampton UK.
April 17-21 1999 American Academy of Neurology, Toronto, CAN - Attended courses: Treatment of myoclonus, neuroimmunology, ophthalmology, atypical movement disorders,
inflammatory muscle
June 1999 Canadian Congress of Neurosciences, Edmonton, Ca., Attended courses in migraine, neurobahaviour, neurophysiology of radiculopathy and plexopathy
January 2000 - Millennium Stroke Conference, Banff, Ca
February 2000 - International Stroke Conference, New Orleans, United States
May 2000 - American Academy of Neurology, San Diego, United States.
Attended courses in: ophthalmology, clinical genetics, neuromuscular update, therapeutics of psychiatric disease in neurology, therapeutics of Parkinson’s disease.
May 2000 TIPS Workshop, University of Calgary, Ca
June 2000 - Canadian Congress of Neurological Science, Ottawa, Ca. Attended Courses in: Mechanisms of Epilepsy, Mechanisms in Neuromuscular disease
July 2001 - NHS Management Course, Staff Development Department, St. Mary’s Hospital, Manchester, UK.
Revised: 2017/11/29 9
March 2002 Stroke - Molecular, Cellular, Pharmacological and Development of New Therapeutics, Taos, New Mexico, USA
April 2002 American Academy of Neurology, Denver USA
April 2002 5th International Workshop on Maturation Phenomenon in Stroke, Banff, Canada
Winter Semester 2003: Basics of Inflammation, University of Calgary
May 2003 International Society of Magnetic Resonance Meeting Workshop: Molecular Imaging Bordeaux France
January 2005, University of Pennsylvannia Neurology Course, Philadelphia, USA
April 2007 Vascular Biology Meeting Sherrington Hotel, Calgary, Canada
May 2007 The 23rd International Symposium on Cerebral Blood Flow, Metabolism & Function (Brain’07) and the 8th International Conference on Quantification of Brain Function
with Pet (BrainPET’07)
June 2008, European Stroke Conference, Nice, France
June 2010, European Stroke Conference, Barcelona, Spain
October 2011, Association of British Neurologists Annual General Meeting, Newcastle UK
May 2012, European Stroke Conference, Lisbon, Portugal
November 2012, Professionalism and Ethics course (through AHS-Provincial Medical Affairs), Edmonton AB
March 2013, 3rd Annual Therapeutic Hypothermia and Temperature Management: Current and Future, Miami FL
May 2013, Getting Things Done Through Influence (University of Calgary Continuing Education)
May 2013, European Stroke Conference, London UK
June 2013, 6th Congress of The International Society for Vascular Behavioural and Cognitive Disorders (VAS-COG), Toronto, ON
July 2013, Alzheimer’s Association International Conference, Boston, MA
September 2013, Advanced Course in Epidemiological Analysis, London UK
May 2014, European Stroke Conference, Nice FR
June 2014, Canadian Neurological Sciences Federation 29th Annual Congress, Banff AB
October 2014, The 9th International Conference on Frontotemporal Dementia (FTD)
February 2015, The International Stroke Conference, Nashville TN
April 2015, The European Stroke Organization Conference, Glasgow UK
Sept 2015, How to Get Great Buy-in for Your Projects (University of Calgary-Cumming School of Medicine Leadership Workshop)
Sept 2015, 7th World Congress of the International Society for Vascular Behavioural and Cognitive Disorders (VAS-COG), Tokyo, JAPAN
February 2016, International Stroke Conference (ISC), Los Angeles CA
May 2016, European Stroke Organisation Conference (ESOC), Barcelona SPAIN
May 2016, CCNA - Workshop on Clinical Trials for Vascular Cognitive Impairment, Banff AB
May 2016, Campus Alberta Neuroscience 2016 International Conference -Promoting Healthy Brain Aging and Preventing Dementia - Research and Translation, Banff AB
January 2017, HBI Neuro Stroke Team Retreat, Winsport Canada, Calgary AB – Provided by the Calgary Stroke Program
Revised: 2017/11/29 10
May 8-9, 2017, 39th Int’l Symposium of the GRSNC – Dementia and Cognition: A Vascular Perspective, Montreal, Quebec
VI. PROFESSIONAL ACTIVITIES
i. Membership in professional and learned societies
Alberta Medical Association (since Oct 1998)
Association of British Neurologists (since Jan 1995)
Canadian Stroke Consortium (since Oct 1998)
Canadian Medial Protective Association (since Jul 1 2005)
College of Physicians and Surgeons of Alberta (since Jan 2001)
General Medical Council, UK (since Jan 1991)
Royal College of Physicians of Edinburgh (since Jan 2003)
Royal College of Physicians and Surgeons of Canada (since Oct 1998)
ii. Professional service
Grant Panels
Member of the Heart and Stroke Foundation of Canada Scientific Review Committee
2004-2016
University of Calgary MSc Examination Committee 2004-Amber Wong (External
Examiner)
Member of Canadian Institute of Health Research Health Professional (Fellowship)
Review Committee 2005-present
University of Calgary Mentorship Committee 2007-present
University of Calgary Graduate Studies Advisory Committee, Sanju Lama 2007-2009
University of Calgary MSc Examination Committee 2009, Sanju Lama (Examiner)
Hotchkiss Brain Institute (HBI) – Robertson Foundation 2009-2011
Grant Reviews
Heart and Stroke Foundation of Canada Scientific Review Committee 2005- (external
reviewer)
Canadian Institute of Health Research 2005- (external reviewer)
Heart and Stroke Foundation of Canada Fellowship Awards ____- (external reviewer)
Medical Research Council (UK) 2005- (external reviewer)
Wellcome Trust Fellowship (UK) 2005- (external reviewer)
Journal Reviewer (journals listed below)
British Medical Journal 2000-
Stroke 2000-
Canadian Journal of Physiology and Pharmacology 2001-2014
Canadian Journal of Neurological Sciences 2003-
Lancet Neurology 2004-
Brain Research 2004-
Revised: 2017/11/29 11
Annals of Neurology 2004-
Journal of Neuroimmunology 2004-
Neuroscience Letters 2005-
American Journal of Neuroradiology 2005-
Journal of Neurology, Neurosurgery and Psychiatry 2005-
Journal of Contrast Media and Molecular Imaging 2005-
Neurology 2006-
Journal of Cerebral Blood Flow Metabolism 2006-
Brain 2006-
Journal of Neuroprotection 2006-
Public Library of Science 2012-
Administrative Activity/Committees
Calgary Stroke Program Executive Committee 2001-
University of Calgary Experimental Imaging Scientific Review Committee 2003-
Division of Neurology Members Meetings 2003-
Participant, Thesis Defence and Examination Committees, Neuroscience Programs and
Psychology 2004
Experimental Imaging Centre Procedures Committee 2005-
Patient Incident and Safety Committee 2009-
Education Director, Calgary Stroke Program Seminar Series 2009-
Editorial Board Member, Frontiers in Neurology 2012-
Department of Clinical Neurosciences Standing Committee 2012-
Neurology Alternative Academic Relationship Plan (NAARP) (Neurology Management
Committee) 2012-
Poster Adjudicator for the HBI Research Day 2013-
Alberta Alternative Relation Plan (AARP) Neurology Membership Committee 2013-
Calgary Health Regional Ethics Board (CHREB) 2013-14
Director, Calgary Stroke Program Mentorship Program 2014-
Graduate Student Supervisory Committee 2014-
Director, Alberta Stroke Program Education Funding Plan (QuICR) 2014-
Chair, Quality Improvement & Clinical Research (QuICR) Educational Committee, 2014-
Director, Stroke Prevention Clinic, Foothills Hospital 2015-
Principal Investigator, Stroke Prevention Clinic Registry 2015-
VII. RESEARCH SUPPORT
Experimental Grants
1999-2001 Alberta Foundation for Health Research. “Acute Stroke-CT vs. MR imaging” (co-investigator) -$500,000
1999-2001 Canadian Stroke Consortium/Hoffmann-La Roche “Canadian Activase in Stroke Effectiveness Study” (co-investigator) -$200,000
Revised: 2017/11/29 12
2000-2003 Heart and Stroke Foundation of Alberta-“Caspase and NF-kB Activation Mediated Inflammation in Cerebral Maturation” (co-investigator)-$195,000
1999-Biochemical Markers in Acute Stroke (BMASS) (co-investigator)
2003- FASTER- Heart and Stroke Foundation (Co-Investigator)-$500,000
2003- FASTER- Canadian Institute of Health Research (Co-Investigator) -$1000,000
Clinical Trial Funding-NIH and Canadian Stroke Consortium (sub-investigator)
1998-1999 GAIN Americas Stroke Study (Glaxo Wellcome), PI: Drs Sacco, S Phillips-$172,500
1998-1999 ECCO 2000- Citicholine Study-(Interneuron Inc.), PI: Dr A Bellevance-$106,000
1998- SPARCL-Lipitor Study-(Parke-Davis), PI- Dr F Marcoux-$140,625
1998- BRAVO-IIb/IIIa Study-PI- Dr G Klein-$65,000
1999-POST- Bristol Myers Squibb- Acute Stroke Study-$181,500
2000-IMS-National Institutes of Health, USA, PI-Dr J Broderick-$30,000
2000- Headfirst-National Institute of Health, USA, PI Dr J Franks-$30,000
2001- BAYER Stroke Randomized Neuroprotective Study, PI Dr Alastair Buchan-$100,000
2001- Reopro Acute stroke Trial, PI Dr Alastair Buchan-$30,000
2001- ASTIN Stroke Randomized Neuroprotective Study PI Dr Alastair Buchan-$80,000
2001- ATLANTIS CT study Using ASPECTS, PI Michael Hill-$100,000
Clinical Trial Funding-NIH and Canadian Stroke Consortium (co-investigator)
2001 -Joint MRC-HSF Partnership program clinical fellowship grant Co-investigator - Validation of the Alberta Stroke Program Acute CT Score using the Canadian Activase for
Stroke Effectiveness Study. July 1, 1999 - June 30, 2001 $44 000.00/y
2003-ECASSII CT scan review for ASPECTS Co-investigator – Operating Grant 2003 Boston University $30 000.00
2003-vascular imaging of acute stroke for identifying predictors of clinical outcome and recurrent ischemic events (VISION)
Revised: 2017/11/29 13
Co-Investigator – Operating grant PI – Andrew Demchuk (University of Calgary)
2003-2006 CIHR $117 736 per year
2003-Fast Assessment of Stroke and Transient ischemic attack to prevent Early Recurrence (FASTER) - A pilot study for a multicentre randomized controlled, double blind trial of
combination anti-platelet therapy versus aspirin and statin therapy to prevent stroke in those
at high-risk of early recurrence after transient ischemic attack or mild stroke.
Co-Investigator – Clinical Trial
PI – Alastair M. Buchan (University of Calgary)
2003-2004 CIHR $408 275.00
2003-ONO Pharmaceuticals Inc. – 3T vs. 1.5T MRI comparison in acute ischemic stroke Co-Investigator Investigator – Clinical Trial sub-study 2003-2004 $30 000.00
2005-3 Trial Clinical trial grant 2005-2010 NIH-NINDS – US$24 million
2003-Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER) Trial Co-Investigator – Clinical Trial Ontario Ministry of Health and Long-Term
Care / Canadian Stroke Consortium / Canadian Stroke Network / Merck Inc. / Calgary Health
Region 2002-2003 $1,257,500
2005-AS Trial Clinical trial grant 2005-2010 NIH-NINDS – US$25 million Role – Co-Investigator
PAST Peer Reviewed Grants
2004-2007 (Jul-Jun) Grant-in-Aid (New Investigator) - Heart and Stroke Foundation of Alberta, NWT and Nunavut “The Characterisation of the Neuroinflammatory Endothelial
Response to Ischemia/Reperfusion by Magnetic Resonance Molecular Imaging” (MRMI)
$49,000 annually for 3 years, totalling $147,000 (Principal Investigator)
2005-2008 Alberta Heritage Foundation for Medical Research Establishment grant $210,000
2005-2008 Alberta Heritage Foundation for Medical Research Equipment Grant $45,000
2006-2009 (Mar-Apr) Operating Grant - Canadian Institute of Health Research “Magnetic Resonance Imaging of Tissue Plasminogen Activator Induced Toxicity Following Ischemic
Stroke: Influence of Aging” $300,000 (Principal Investigator)
2007-2010 (Jul-Jun) Grant-in-Aid (Renewal) – Heart and Stroke Foundation of Alberta, NWT and Nunavut, “The Characterisation of the Neuroinflammatory Endothelial Response to
Ischemia/Reperfusion by Magnetic Resonance Molecular Imaging” (MRMI) $54,000
annually for 3 years, totalling $164,000 (Principal Investigator)
Revised: 2017/11/29 14
2007-2010 (Apr-Mar) Operating Grant - Canadian Institute of Health Research “Resveratrol neuroprotection for stroke recurrence following minor stroke” $120,000 annually for 3 years,
totaling $360,000 (Co-applicant)
CURRENT Peer Reviewed Grants
2009-2015 (Jun1-Dec31) Operating Grant – Pfizer – “Cognition and brain ATrophy after
Cerebrovascular event in High risk patients.” $50,000 (Co-principal investigator)
2012-2017 (Nov26-Nov30) Operating Grant (Ongoing/Renewed) – Department of Clinical
Neurosciences – Acute Quantitated T1 and T2. Stroke Prevention Program, $25,000;
Department of Clinical Neurosciences, 25,000; $50,000 in total.
2013-2015 (Mar1-Jun30) Studentship Grant – Katthy Taylor Vascular Dementia Research
Chair – “Imaging Biomarker Diagnosis of Cognitive Impairment in Mild Stroke and TIA.”
$37,000.00 over 3 years
2011-2016 (Apr-Mar) Operating Grant - Canadian Institute of Health Research
“Pathophysiology and treatment of stroke recurrence” $114,900 annually over 5 years,
totaling $574,500 (Co-applicant)
2014-2019 (Apr-Mar) Operating Grant - Canadian Institute of Health Research.
Canadian Consortium on Neurodegeneration in Aging. “Vascular Illness and its Impact on
Neurodegenerative Diseases.” $750,000 over 5 years (clinical) (Co-applicant)
2014-2019 (Jul-Jun) Alberta Innovates–Health Solutions, Collaborative Research &
Innovation Opportunities Grant (Dec 2013) - Quality Improvement Clinical Research
(QuICR): Alberta Stroke Program. $5M over 5 years (Co-applicant and Educational Lead)
2014-2017 (Jul-Jun) Grant-in-Aid - Heart and Stroke Foundation of Canada “Recanalization
following Endovascular treatment and imaging of PErfusion, Regional InFarction and
atrophy to Understand Stroke Evolution (REPERFUSE).” $197,505.00 over 3 years
(Principal Investigator)
2014-2017 (Oct1-Jun30) Operating Grant - The Weston Brain Institute – “A blood test for
Alzheimer’s based on fluorescence spectroscopy.” $150,000 over 3 years (Co-applicant)
2014-2019 (Apr-Mar) Operating Grant - Canadian Institute of Health Research – “Canadian
Stroke Trials for Optimized Results (CaSTOR).” $1.5M over 5 years (Co-applicant)
2016-2019 (Jul-Jun) 2016/17 Grant-in-Aid - Heart and Stroke Foundation of Canada.
“Predementia Neuroimaging of Transient Ischemic Attack (TIA) – PREVENT Study”
$293,000 over 3 years (Principal Investigator)
2016-2019 (Jul-Jun) 2016/17 Grant-in-Aid – Heart and Stroke Foundation of Canada.
Revised: 2017/11/29 15
“TEMPO-2 – A randomized controlled trial of TNK-tPA versus standard of care for minor
ischemic stroke with proven occlusion.” $256,990 over 3 years (Co-Applicant)
2017-2022 (Jul-Jun) Project Scheme Grant – Canadian Institutes of Health Research, Fall 2016. “A
Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single- dose Design
to Determine the Efficacy and Safety of Intravenous NA-1 in Subjects with Acute Ischemic Stroke
Undergoing Endovascular Thrombectomy (ESCAPE-NA1 Trial) ” $2,445,000 over 5 years (Co-
Applicant)
2018-2021 Project Scheme Grant- Canadian Institute of Health Research, Fall 2017
“REPERFUSE NA1” $467,000 over 3 years (Principal Investigator)
2018-2021 Grant in Aid- Heart and Stroke Foundation of Canada, Fall 2017 “REPERFUSE
NA1” $300,000 over 3 years (Principal Investigator)
2018-2023 Project Scheme Grant-Canadian Institute of Health Research, Fall 2017 “Tempo
2” $2.1 M, over 5 years (Site PI, Co-investigator).
PENDING Peer Reviewed Grants
2018-2021 (Apr-Mar) Project Scheme Grant – Canadian Institutes of Health Research (Fall 2017. “Magnetic Resonance Imaging Evaluation of NA1 Neuroprotection on Infarct Growth
Following Endovascular Treatment for Acute ischemic Stroke.” $610,000 over 3 years
(Principal Investigator)
2018-2021 (Jul-Jun) Grant-in-aid Heart - Heart and Stroke Foundation of Canada (Fall 2017) “Magnetic Resonance Imaging Evaluation of NA1 Neuroprotection on Infarct Growth
Following Endovascular Treatment for Acute Ischemic Stroke.” $300,000 over 3 years
(Principal Investigator)
2018-2023 (Apr-Mar) Project Scheme Grant – Canadian Institutes of Health Research (Fall 2017). “TEMPO-2 – A randomized controlled trial of TNK-tPA versus standard of care for
minor ischemic stroke with proven occlusion.” $2,605,000 over 5 years (Co-Applicant)
Salary Supported Peer-Reviewed Grants
2001-2003 Canadian Institute of Health Research/ Heart and Stroke Foundation of Canada Postdoctoral Fellowship (Declined)
2001-2003 Alberta Heritage Foundation for Medical Research Postdoctoral Fellowship
2005-2008 Alberta Heritage Foundation of Medical Research Clinical Investigator
2005-2010 Canadian Institute of Health Research New Investigator (declined)
2005-2010 Heart Stroke Foundation of Canada New Investigator
2005/2006 Henry JM Barnett Research Scholarship award ($15,000)
2006 University of Calgary Young Innovator Award (20,000)
2008-2012 Alberta Heritage Foundation of Medical Research Clinical Investigator (Renewed) ($50,000)
Revised: 2017/11/29 16
Equipment Grant (Non Peer-Reviewed)
Western Economic Diversification 2001 ($221,000)
VIII. INVITED LECTURES
“Headache in Neurophthalmology”. Neurophthalmology Course. Manchester University. December 1997.
“Clinical signs and symptoms of acute stroke”. Beverly Care Nursing Home November 1998.
“Stroke Prevention”. University of Calgary Therapeutics Course May 1999.
“Symptoms and signs of ischemic stroke”. University of Calgary Neuroscience Course, September 1999.
“Thresholds of Cerebral Ischemia” Millennium Stroke Conference, Banff, Ca, January 2000.
“Animal Stroke Models” Imaging Network Ontario Symposium, Toronto Colony Hotel, Toronto, Canada, September 2002.
“From Animal Stroke Models Towards Molecular Imaging”, University of Calgary, June 2003.
“The Filament Middle cerebral Artery Occlusion Model in Mice”, Memorial University, Newfoundland, July 2003.
“Macrobleeds and Microbleeds” Canadian Congress for the Neurosciences, Calgary July 2004.
Developmental Molecular MRI in Stroke. 4th National Research Council Nanotechnology Meeting, Edmonton, Alberta June 2006.
Molecular Magnetic Resonance Imaging: An Update Cerebral Vascular Conference, Ottawa, Canada, June 2007.
Trials and Tribulations of Molecular Magnetic Resonance Imaging. Advance Bio-Imaging Technology Conference, Banff, Alberta, Canada, September 16-18, 2009.
Vascular Cognitive Impairment: An Update. NHNN, Queen Square, UK, December 14, 2011.
Can we extend the Acute Stroke Treatment Window? Manchester Clinical Neuroscience, Hope Hospital, UK, May 18, 2012.
Revised: 2017/11/29 17
Vascular Cognitive Impairment. Short Course in Dementia, NHNN, Queen Square, UK, May 22, 2012.
Deciphering Vascular Dementia. University of Calgary, Calgary, Alberta. June 14, 2012.
The Impact of Preventing Recurrent Stroke: Canadian Neurological Sciences Federation (CNSF) 29th Annual Congress, June 5, 2014. Banff AB June 3-6, 2014.
Insights into Reperfusion Injury. Lecture title, “Tight Junction Protein Degradation in Ischemia Reperfusion”. International Stroke Conference, Los Angeles, CA, February 17-19,
2016.
Canadian Consortium on Neurodegeneration in Aging. Workshop – Banff Springs Conference Centre, Banff AB May 23-27, 2016. Talk entitled, “Neuroimaging surrogates and
outcome measures of dementia and predementia.”
Tight Junctions in Ischemia Reperfusion. International Stroke Conference, Los Angeles CA, Feb 17, 2016.
Neuroimaging Surrogates and Outcomes in Vascular Cognitive Impairment. 2016 International Conference: Promoting Healthy Brain Aging and Preventing Dementia –
Research and Translation, Banff AB, May 23-27, 2016.
HBI Neuro Stroke Team Retreat, Winsport, Calgary AB “The delayed secondary injury that follows ischemia during cerebral blood flow restoration: a target for human stroke.” January
13, 2017.
“Modifiable vascular risk factors and biomarkers in vascular cognitive impairment …”. Dementia and Cognition: A Vascular Perspective (39th Int’l Symposium of the GRSNC,
Montreal, QC May 8-9, 2017).
IX. PRESENTATIONS
“Myasthenic Myopathy Revisited.” North West Regional Neuromuscular Meeting Queen Elizabeth Hospital Birmingham UK, March 1997.
“Two Cases of Muscle Hypertrophy”. North West Regional Neuromuscular Meeting, Liverpool UK, March 1998.
Early CT changes in hyperacute stroke (oral). University of Calgary Clinical Research day, McMahon Stadium March16 1999.
The electroencephalogram in Dementia with Lewy bodies (poster). Association of British Neurologists, Southampton, March 22-23 1999.
Revised: 2017/11/29 18
Intra-arterial thrombolysis in 5 cases of basilar artery thrombosis (platform). Canadian Congress of Neurological Sciences, Edmonton, Ca, June 16 1999.
Thrombolysis in acute ischemic stroke: the Calgary experience (platform). Canadian Congress of Neurological Sciences, Edmonton, Ca, June 17 1999.
The inter-observer reliability of the Alberta Stroke Program CT scoring system (poster).
Canadian Congress of Neurological Sciences, Edmonton, Ca, June 17 1999.
The use and validity of a quantitative CTscore in acute hemispheric stroke in predicting outcome prior to thrombolytic treatment. Association of British Neurologists, London.
September 1999. (platform)
Use and validity of a quantitative score in early cerebral ischemia. American Neurological Association. Seattle October 1999.
The validity and reliability of a novel quantitative CT Score in predicting outcome prior to thrombolytic treatment. 25th International Stroke Conference. New Orleans, United States.
February 2000. (platform)
The hyperdense sylvian fissure branch sign: a marker of thromboembolic stroke. 35th Canadian Congress of Neurological Sciences, Ottawa, Ca. June 2000. (platform)
An analysis of patient eligibility for alteplase in acute ischemic stroke. 35th Canadian Congress of Neurological Sciences, Ottawa, Ca June 2000. (platform)
Why stroke patients don’t receive alteplase? An analysis of patient eligibility: Implications of improving clinical impact by increasing future treatment numbers. American Neurological
Association, September 2000 Boston, USA.
A comparison of CT versus MR imaging in acute stroke using ASPECTS: Will the “new” replace the “old” as the preferred imaging modality? American Stroke Association Meeting,
Ft Lauderdale, USA February 2001.
The Role of Repeat CT for predicting fatal outcome following massive middle cerebral artery territory infarction. American Stroke Association Meeting, Ft Lauderdale, USA February
2001.
Why stroke patients don’t receive t-PA? An analysis of patient eligibility: implications for improving clinical impact by increasing future treatment numbers. American Stroke
Association Meeting, Ft Lauderdale, USA February 2001.
The hyperdense sylvian fissure branch sign: a marker of thromboembolic stroke. American Stroke Association Meeting, Ft Lauderdale, USA February 2001.
Revised: 2017/11/29 19
A comparison of CT versus MR imaging in acute stroke using a topographical quantitative system (ASPECTS). American Academy of Neurology, Philadelphia, USA, April 2001.
The Role of Repeat CT for predicting fatal outcome following massive middle cerebral artery territory infarction. Canadian Conference of Neuroscience, Halifax, Canada, June 2001.
A comparison of Computed Tomography with Diffusion Weighted Imaging in Hyperacute Stroke using a Systematic Quantitative System (ASPECTS). Association of British
Neurologists, Durham, UK, September 2001.
The probability of MRA flow signal abnormality with quantified CT ischemic change: Targets for future therapeutic trials. American Academy of Neurology, Denver, Colorado,
USA, April 2002.
Magnetic Resonance Molecular Imaging (MRMI) of Early Endothelial Activation in Focal Ischemia in Mice. ISMRM Molecular Imaging Workshop, Bordeaux, France 2003.
Magnetic Resonance Molecular Imaging (MRMI) of Early Endothelial Activation in Focal Ischemia in Mice. American Neurological Association, San Francisco, USA, 2003.
The Study of Temperature Regulation in a Mouse Model of Focal Ischemia: An Assessment of Behavioral Outcomes and Histological Injury. Neuroscience Meeting, San Diego, USA 2003.
Magnetic Resonance Molecular Imaging of Activated Endothelium in Acute Stroke Using a Targeted Iron-Oxide Nanoparticle Contrast Agent. Brain 2007, Osaka, Japan.
Quantified T1 and T2 as useful adjuncts to DWI for early infarct detection in permanent and transient MCAO. Accepted for poster presentation at the Brain '07: 23rd International
Symposium on Cerebral Blood Flow and Metabolism at Osaka, Japan, May 20-24th 2007.
Magnetic Resonance Molecular Imaging of Endothelial Activation in Acute Stroke in Wild Type and P-selectin Deficient Mice. European Stroke Conference, Nice, France, May 15, 2008
(oral presentation).
Quantitative MRI reveals the elderly ischemic brain is susceptible to increased early blood-brain barrier permeability following tissue plasminogen activator related to claudin 5 and
occludin disassembly. European Stroke Conference, Barcelona, Spain, May 7, 2009 (oral
presentation).
Stroke Course Chair Canadian Neurological Society Federation, June 5, 2014.
Revised: 2017/11/29 20
X. PUBLICATIONS
1. Barber PA, Schady W. A syndrome of lower cranial nerve palsies. Journal of Neurology, Neurosurgery and Psychiatry 1998; 65; 133. [Reviewed subject background and wrote
manuscript]
2. Barber PA, Sieredzan KS, Schady WS. Sagittal sinus obstruction and tuberculosis abscess. Acta Scandinavica Neurologica 1999; 99(3): 202-203. [Reviewed subject background and
wrote manuscript] (NOT on Web of Science website)
3. Barber PA, Varma AR, Lloyd JJ, Haworth B, Snowden JS, Neary D. The electroencephalogram in dementia with Lewy bodies. Acta Scandinavica Neurologica 2000;
101(1):53-56. [Reviewed subject background wrote manuscript]
4. Buchan AM, Barber PA, Karbalai HG, Demchuk AM, Hoyte KM, Klein GM, Feasby TE. Effectiveness of t-PA in acute ischemic stroke: outcome relates to appropriateness.
Neurology 2000; 54:679-684. [Major contribution to study design, methodology, data
collection, and wrote manuscript]
5. Alexandrov AV, Demchuk AM, Felberg RA, Christou I, Barber PA, Burgin WS, Malkoff M, WosnerGW, Grotta JC. Dramatic improvement during intravenous TPA infusion
combined with 2MHz transcranial Doppler monitoring is associated with complete
recanalization. Stroke 2000; 31:610-614. [Contributed to data collection and proof read
manuscript]
6. Hill MD, Barber PA, Demchuk AM, Newcommon NJ, Green T, Buchan AM. The Calgary Regional Stroke Program: Building a brain attack team for Thrombolytic therapy in acute
ischemic stroke. Can Med Assc J 2000; 162: 1589-1593. [Major contribution to study
design, methodology, data collection, and wrote manuscript]
7. Barber PA, Alexandrov AV, Demchuk AM. Transcranial Doppler sonography in acute stroke. Journal Neurol Neurosurg and Psychiatry 2000; 68:532. [Major contribution.
Reviewed subject background wrote manuscript]
8. Barber PA, Demchuk AM, Zhang J, Buchan AM for the ASPECTS Study Group. Validity and reliability of a quantitative CT score in hyperacute stroke predicts outcome before
thrombolytic therapy. Lancet 2000; 355(9216):1670-1674. [Major contribution to study
design, methodology, data collection, and wrote manuscript]
9. Hill MD, Barber PA, Demchuk AM, Buchan MD. Thrombolysis in acute stroke works. BMJ 2000; 321: 299. [Major contribution to literature search and background and co-wrote]
10. Hill MD, Barber PA, Takahashi, Demchuk AM, Feasby TE, Buchan AM. Anaphylactoid reactions during rtPA treatment of acute ischemic stroke. CMAJ 2000; 169:1281-1284.
[Major contribution to study design, methodology, data collection, and wrote manuscript]
Revised: 2017/11/29 21
11. Barber PA, Demchuk AM, Buchan AM. Intra-arterial therapy in acute stroke. Lancet 2000: 356; 1112. [Major contribution. Reviewed subject background wrote manuscript]
12. Barber PA, Hill MD, Demchuk AM, Buchan AM. Doubts, fears and misconceptions. What is the future of thrombolysis in acute stroke? Canadian. Journal of Neurological Sciences
2000; 27:283-287. [Major contribution to literature search and background and wrote
manuscript]
13. Barber PA, Demchuk AM, Zhang J, Hudon ME, Pexman W, Hill MD, Buchan AM. The hyperdense sylvian fissure MCA “dot” sign. A CT marker of acute cerebral ischemia. Stroke
2001; 32:84-88. [Major contribution to study design, methodology, data collection, and
wrote manuscript]
14. Demchuk AM, Burgin WS, Christou I, Felberg RA, Barber PA, Hill MD, Alexandrov AV. Thrombolysis in brain ischemia (TIBI) TCD flow grades predict clinical severity, clinical
recovery and mortality in intravenous TPA treated patients. Stroke 2001; 32: 89-93.
[Contributed to data collection and proof read manuscript]
15. Hill MD, Barber PA, Demchuk AM, Sevick RJ, Frayne R, Buchan AM. Symptomatic hemorrhage after alteplase therapy not due to silent ischemia. BMC Neurology 2001; 1: 1.
[Contributed to data collection and proof read manuscript]
16. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA treatment? An analysis of patient eligibility. Neurology 2001; Apr
24;56(8):1015-20. [Major contribution to study design, methodology, data collection, and
wrote manuscript]
17. Barber PA, Auer RN, Buchan AM, Sutherland GS. Understanding and managing stroke Canadian Journal of Physiology and Pharmacology 2001; 79(3):283-296. [Major
contribution. Reviewed subject background wrote manuscript]
18. Pexman WJH, Barber PA , Hill MD , Sevick RJ, Demchuk AM, Hudon M, Hu WY, Buchan AM. Use of the Alberta Stroke Program Early CT Score (ASPECTS) for assessing
CT scans in patients with acute stroke. Am J Neuroradiol 2001 Sep; 22(8):1534-42. [Major
contribution to study design, methodology, data collection, and wrote manuscript]
19. Hill MD, Barber PA, Demchuk AM, Newcommon NJ, Cole-Haskayne A, Ryckborst K, Sopher L, Button A, Hu W, Hudon ME, Morrish W, Buchan AM. Acute IV-IA
Revascularization Therapy for Severe Ischemic Stroke. Stroke 33:279-282, 2002. [Major
contribution to study design, methodology, data collection, and wrote manuscript]
20. Hill MD, Zhang J, Buchan AM. Methodology for the Canadian Activase for Stroke Effectiveness Study (CASES). CASES Investigators. Can J Neurol Sci 2001; Aug;28:232-8.
[PA Barber collaborator and contributed to data collection]
Revised: 2017/11/29 22
21. Demchuk AM, Tanne D, Hill MD, Kasner SE, Hanson S, Grond M, Levine SR and the Multicentre tPA Stroke Survey Group. * Predictors of good outcome after intravenous rt-PA
for acute ischemic stroke: The multi-centre tPA acute stroke survey. Neurology 2001;
57:474-480. [*PA Barber collaborator]
22. Yang JJ, Hill MD, Morrish WF, Hudon ME, Barber PA, Demchuk, AM, Sevick RJ, Frayne R. Comparison of Pre- and Post-Contrast 3D TOF MR Angiography for Distal Intra-cranial
Branch Occlusion in Acute Ischemic Stroke. American Journal of Neuro Radiology AJNR
2002 Apr; 23(4):557-67. [Major contribution to data collection and co-author]
23. Chauhan N, Zhao Z, Barber PA, Buchan AM. Experimental Ischemia Lessons in Clinical Stroke Medicine. Curr Opin Neurol. 2003 Feb; 16(1):65-71. [Major contribution. Reviewed
subject background and co- wrote manuscript]
24. Hill MD, Lye T, Moss H, Barber PA, Demchuk, AM, Newcommon NJ, Green TL, Kenney C, Cole-Haskayne A, Buchan AM. Hemi-orolingual Angioedema after Alteplase Treatment
of Stroke is Associated with Angiotensin Converting Enzyme Inhibitor Use. Neurology.
2003 May 13; 60(9):1525-7. [Major contribution to study design, methodology, data
collection, and co-wrote Manuscript]
25. Barber PA, Zhang J, Kasner S, Krieger D, Demchuk AM. Computed tomographic parameters predicting fatal outcome in large middle cerebral artery infarction.
Cerebrovascular Disease 2003; 16:230-235. [Major contribution to study design,
methodology, data collection, analysis and wrote manuscript]
26. Coutts SB, Simon JE , Tomanek AI , Barber PA, Chan J,Hudon ME, Frayne R, Eliasziw M, Buchan AM, Demchuk AM. Reliability In Assessment of DWI/PWI Mismatch
Implications for clinical trial design. Stroke 2003; 34: 1681 – 1683. [Major contribution to
study design, data collection, and co-wrote]
27. Coutts SB, Barber PA, Demchuk AM, Hill MD, Pexman W, Hudon ME, Buchan AM. Mild Neurological Symptoms despite Middle Cerebral Artery Occlusion. Stroke 2004;
35:469-471. [Major contribution to study design, methodology, data collection, and co-
wrote Manuscript]
28. Pexman JH, Hill MD, Buchan AM, Demchuk AM, Barber PA, Simon JE, Coutts SB. Hyperacute stroke: experience essential when reading unenhanced CT scans. AJNR Am J
Neuroradiol. 2004 Mar;25:516.
29. Hoyte L, Barber PA, Hill MD. The rise and fall of NMDA antagonist for ischemic stroke. Current Molecular Medicine 2004;4:127-132. [Major contribution to the literature review
and manuscript writing]
30. Barber PA, Demchuk AM, Hill MD, PexmanW, Hudon M, Frayne R, Buchan AM. The probability of middle cerebral artery MRA flow signal abnormality with quantified CT
Revised: 2017/11/29 23
ischemic change: Targets for future therapeutic studies. JNNP 2004;75:1426-30. [Major
contribution to study design, methodology, data collection, and wrote manuscript]
31. Coutts SB, Hill MD, Barber PA, Hu WY, Simon JE, Fischer KL, Buchan AM, Demchuk AM for the VISION study group. Interobserver variation of ASPECTS in real time. Stroke
2004; 35:e103-105. [Major contribution to study design, methodology, data collection, and
co-wrote manuscript]
32. Barber PA, Foniok T, Kirk D, Buchan AM, Sébastien Boutry , Muller R, Tuor UI. Magnetic Resonance Molecular Imaging (MRMI) of Early Endothelial Activation in Focal
Ischemia in Mice. Ann Neurol 2004 56(1):116-20. [Major contribution to study design,
methodology, data collection, and wrote manuscript]
33. Barber PA, Hoyte L, Colbourne F, Buchan AM. Temperature Regulated Model of Focal Ischemia in the Mouse: A Study with Histopathological and Behavioral Outcomes. Stroke
2004; 35: 1720-1725. [Major contribution to study design, methodology, data collection,
and wrote manuscript]
34. Gagnon A, Barber PA. Hyperacute post-thrombolysis hematoma by MRI. Neurology 2004 Oct 26; 63(8):1534. [Major contribution to writing of manuscript and data collection]
35. Buchan AM, Barber PA. From Bench to Bedside: Evolving Experimental MRI Technology in Stroke. Society of Neuroradiologists. 2004: 133-137. (NOT on Web of
Science website)
36. Saqqur M, Demchuk AM, Hill MD, Dean N, Schebel M, Kennedy J, Barber PA, Shuaib A. Bedside emergency transcranial Doppler diagnosis of severe carotid disease using orbital
window examination. J Neuroimaging. 2005 Apr; 15(2): 138-43.
37. Coutts SB, Simon JE, Eliasziw M, Sohn CH, Hill MD, Barber PA, Palumbo V, Kennedy J, Roy J, Gagnon A, Scott JN, Buchan AM, Demchuk AM. Triaging transient ischemic attack
and minor stroke patients using acute magnetic resonance imaging. Ann Neurol. 2005 Jun;
57(6): 848-54. PMID: 15929051.
38. Barber PA, Hill MD, Eliasziw M, Demchuk AM, Pexman JH, Hudon ME, Tomanek A, Frayne R, Buchan AM; ASPECTS Study Group. Imaging of the brain in acute ischaemic
stroke: comparison of computed tomography and magnetic resonance diffusion-weighted
imaging. J Neurol Neurosurg Psychiatry. 2005 Nov;76(11):1528-33. [Major contribution
to study design, methodology, data collection, and wrote manuscript]
39. Demchuk AM, Hill MD, Barber PA, Silver B, Patel S, Levine SR; NINDS rtPA Stroke Study Group, NIH. Importance of early ischemic computed tomography changes using
ASPECTS in NINDS rtPA Stroke Study. Stroke 2005 Oct;36(10):2110-5. Epub 2005 Sept
15.
Revised: 2017/11/29 24
40. Barber PA, Hoyte L, Foniok T, Kirk D, Buchan AM, Tuor U. Early T1 and T2-weighted MRI signatures of transient and permanent middle cerebral artery occlusion in a murine
stroke model studied at 9.4 T. Neuroscience Letters 2005 388(1):54-9.
41. Pettersen JA, Hill MD, Demchuk AM, Morrish W, Hudon ME, Hu W, Wong J, Barber PA, Buchan AM. Intra-arterial thrombolysis for central retinal artery occlusion. CJNS
2005; Nov;32(4):507-11.
42. Barber PA, Powers W. MR DWI does not substitute for stroke severity scores in predicting stroke outcome. Neurology 2006 Apr 25;66(8):1138-9.
43. Pettersen JA, Pexman JH, Barber PA, Demchuk AM, Buchan AM, Hill MD. Insular cortical ischaemia does not independently predict acute hypertension or hyperglycaemia
within 3 h of onset. J Neurol Neurosurg Psychiatry 2006; 77(7):885-7.
44. Toth C, Schmidt AM, Tuor UI, Francis G, Foniok T, Brussee V, Kaur J, Yan SF, Martinez JA, Barber PA, Buchan A, Zochodne DW. Diabetes, leukoencephalopathy and rage.
Neurobiol Dis. 2006 Jun 29. [Epub ahead of print].
45. Barber, PA. Is diffusion-weighted imaging helpful in determining the source of stroke? [Commentary]. Nature Clinical Practice Neurology 2006 Aug 01; 2, 424-425.
46. Subramaniam, S, Peutz V, Dwiazlowksi, I, Barber PA. Cerebral Microhemorrhages in a patient with a mycotic aneurysm: Relevance of T2*-GRE in SBE. Neurology 2006 Nov
14;67(9):1697.
47. Subramaniam S, Demchuk AM, Watson T, Barber PA, Hill MD. Unexpected Post Hemorrhagic Hydrocephalus in Patients Treated with rFVIIa. Neurology 2006
26;67(6):1096.
48. Dzialowski I, Pexman JHW, Barber PA, Demchuk AM, Buchan AM, Hill MD on behalf of the CASES Investigators. Asymptomatic hemorrhage after thrombolysis may not be
benign: Prognosis by hemorrhage type in the CASES registry. Stroke 2007; 38:75-79.
49. Hoyte LC, Papadakis M, Barber PA, Buchan AM. Improved regional cerebral blood flow is important for the protection seen in a mouse model of late phase ischemia
preconditioning. Brain Research 2006; 1121(1):231-7.
50. Sun,HS , Feng, ZP, Barber, PA, Buchan AM, French RJ. Kir6.2-containing ATP-sensitive potassium channels protect cortical neurons from ischemic/anoxic injury in vitro and in
vivo. Neuroscience 2007; 144(4):1509-15.
51. Gofton T, Barber PA. Anterior Spinal Artery Stroke at the Cervical Medullary Junction. CJNS 2006 Nov; 33(4):418-20.
javascript:AL_get(this,%20'jour',%20'Neurology.');http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=Abstract&list_uids=16788017&query_hl=1&itool=pubmed_docsum
Revised: 2017/11/29 25
52. Filfil R, Jin A, Tolkatchev D, Tonan1 K, Gingras R, Barber PA, Ni F. Development of Polyvalent Peptide-Conjugated Magnetic Nanoparticles (MNPs) for Targeted In-Vivo
Imaging of Micro-Thrombi. Proceedings for the Society of Peptides 2007.
53. Puetz V, Sylaja PN, Coutts SB, Hill MD, Dzialowski I, Mueller P, Becker U, Urban G, O'Reilly C, Barber PA, Sharma P, Goyal M, Gahn G, von Kummer R, Demchuk AM.
Extent of hypoattenuation on CT angiography source images predicts functional outcome in
patients with basilar artery occlusion. Stroke 2008 Sep;39(9):2485-90.
54. Puetz V, Dzialowski I, Hill MD, Subramaniam S, Sylaja PN, Krol A, O'Reilly C, Hudon ME, Hu WY, Coutts SB, Barber PA, Watson T, Roy J, Demchuk AM. Intracranial
thrombus extent predicts clinical outcome, final infarct size and hemorrhagic transformation
in ischemic stroke: the clot burden score. Int J Stroke 2008 Nov; 3(4):230-6.
55. Demchuk AM, Khan, F, Hill MD, Barber PA, Silver B, Patel S, Levine SR; NINDS rt-PA Stroke Study Group. Importance of leukoaraiosis on CT for tissue plasminogen activator
decision making: evaluation of the NINDS rt-PA Stroke Study. Cerebrovasc Dis. 2008;
26(2):120.
56. Zhu HF, Newcommon NN, Cooper ME, Green TL, Seal B, Klein G, Weir NU, Coutts SB, Watson T, Barber PA, Demchuk AM, Hill MD. Impact of a stroke unit on length of
hospital stay and in-hospital case fatality. Stroke 2009 Jan; 40(1):18-23.
57. Filfil R, Jin A, Tolkatchev D, Tonan1 K, Gingras R, Barber PA, Ni F. Development of polyvalent peptide-conjugated magnetic nanoparticles for targeted in-vivo imaging of
micro-thrombi. Adv Exp Med Biol. 2009; 611:415-6.
58. Kaur J, Tuor UI, Zhao Z, Petersen J, Jin AY, Barber PA. Quantified T1 as an adjunct to apparent diffusion coefficient for early infarct detection: a high-field magnetic resonance
study in a rat stroke model. Int J Stroke 2009; June 4(3):159-68.
59. Jin A.Y, Tuor U.I, Rushforth D, Filfil R, Kaur J, Ni F, Tomanek B, Barber PA. Magnetic resonance molecular imaging of post-ischemia neuroinflammation with a P-selectin
targeted iron oxide nanoparticle. Contrast Media Mol Imaging 2009 Nov-Dec; 4(6):305-11.
60. Qiao M., Zhang Z., Barber PA, Foniok T, Sun S, Tuor UI. Development of a model of recurrent stroke consisting of a mild transient stroke followed by a second moderate stroke
in rates. J. Neurosci Methods 2009 Nov 15;184(2):244-50.
61. Zhao Z, Tuor U, Barber PA. Chronic treatment with Losartan and Cerebral Ischemic Tolerance. J Exp Stroke Transl. Med 2(2): 32-40, 2009. (NOT on Web of Science website)
62. Jin AY, Tuor UI, Rushforth D, Kaur J, Muller RN, Petterson JL, Boutry S, Barber PA. Reduced blood brain barrier breakdown in P-selectin deficient mice following ischemic
stroke: a future therapeutic target for treatment of stroke. BMC Neurosc 2010 Feb 2;11:12.
http://www.ncbi.nlm.nih.gov/pubmed/18617663?ordinalpos=6&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSumhttp://www.ncbi.nlm.nih.gov/pubmed/18617663?ordinalpos=6&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSumhttp://www.ncbi.nlm.nih.gov/pubmed/18811738?ordinalpos=5&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSumhttp://www.ncbi.nlm.nih.gov/pubmed/18811738?ordinalpos=5&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSumhttp://www.ncbi.nlm.nih.gov/pubmed/18811738?ordinalpos=5&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSumhttp://www.ncbi.nlm.nih.gov/pubmed/19008467?ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSumhttp://www.ncbi.nlm.nih.gov/pubmed/19008467?ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum
Revised: 2017/11/29 26
63. Shobha N, Bhatia R, Barber PA. Dental procedures and stroke: a case of vertebral artery dissection. J Can Dent Assoc. 2010: 76:a82.
64. Barber PA, Wechsler LR. The ischemic penumbra: from celestial body to imaging technology. Neurology 2010 Sep 7;75(10):844-5.
65. Kaur J, Tuor U, Zhoa Z, Barber PA. Quantitative MRI reveals the elderly ischemic brain is susceptible to increased early blood-brain barrier permeability following tissue plasminogen
activator related to claudin 5 and occludin disassembly. J Cereb Blood Flow Metab. 2011
Sep 01;31(9):1874-85. (PMID: 21610723)
66. Bhatia R, Bal SS, Shobha N, Menon BK, Tymchuk S, Puetz V, Dzialowski I, Coutts SB, Goyal M, Barber PA, Watson T, Smith EE, Demchuk AM; Calgary CTA Group. CT
angiographic source images predict outcome and final infarct volume better than
noncontrast CT in proximal vascular occlusions. Stroke 2011 Jun;42(6):1575-80.
67. Coutts SB, Hill MD, Eliasziw M, Fischer K, Demchuk AM; for the VISION study group. Final 2 year results of the vascular imaging of acute stroke for identifying predictors of
clinical outcome and recurrent ischemic eveNts (VISION) study. BMC Cardiovasc Disord.
2011 Apr 23;11:18.
68. Demchuk AM, Dowlatshahi D, Rodriguez-Luna D, Molina CA, Blas YS, Dzialowski I, Kobayashi A, Boulanger JM, Lum C, Gubitz G, Padma V, Roy J, Kase CS, Kosior J, Bhatia
R, Tymchuk S, Subramaniam S, Gladstone DJ, Hill MD, Aviv RI; PREDICT/Sunnybrook
ICH CTA study group. Prediction of haematoma growth and outcome in patients with
intracerebral haemorrhage using the CT-angiography spot sign (PREDICT): a prospective
observational study. Lancet Neurol. 2012 Apr;11(4):307-14.
69. Clark D, Tuor UI, Thompson R, Institoris A, Kulynych A, Zhang X, Kinniburgh DW, Bari F, Busija DW, Barber PA. Protection against recurrent stroke with resveratrol: endothelial
protection. PLoS One. 2012;7(10):e47792. Epub 2012 Oct 17.
70. Barber PA, Rushforth D, Agarwal S, Tuor UI. Infrared optical imaging of matrix metalloproteinases (MMPs) up regulation following ischemia reperfusion is ameliorated by
hypothermia. BMC Neurosci. 2012 Jun 28; 13:76.
71. Hill MD, Kenney C, Dzialowski I, Boulanger JM, Demchuk AM, Barber PA, Watson TW, Weir NU, Buchan AM. Tissue Window in Stroke Thrombolysis study (TWIST): a safety
study. Can J Neurol Sci. 2013 Jan;40(1):17-20. PubMed PMID: 23250122
72. Barber PA. Magnetic resonance imaging of ischemia viability thresholds and the neurovascular unit. Sensors 2013 May 27;13(6):6981-7003.
73. Phan TG, Demchuk A, Srikanth V, Silver B, Patel SC, Barber PA, Levine SR, Hill MD. The NINDS rt-PA Stroke Study Group. Proof of concept study: relating infarct location to
stroke disability in the NINDS rt-PA trial. Cerebrovasc Dis. 2013;35(6):560-5.
http://www.ncbi.nlm.nih.gov/pubmed/20633337http://www.ncbi.nlm.nih.gov/pubmed/20633337http://www.ncbi.nlm.nih.gov/pubmed?term=%22Coutts%20SB%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Hill%20MD%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Eliasziw%20M%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Fischer%20K%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Demchuk%20AM%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22VISION%20study%20group%22%5BCorporate%20Author%5D
Revised: 2017/11/29 27
74. Camden MC, Hill MD, Demchuk AM, Poppe AY, Shobha N, Barber PA, Coutts SB. Historic stroke motor severity score predicts progression in tia/minor stroke. Can J Neurol
Sci. 2014 Jan;41(1):19-23.
75. Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, Vaid H, O'Donnell M, Laupacis A, Côté R, Sharma M, Blakely JA, Shuaib A, Hachinski V, Coutts SB, Sahlas DJ,
Teal P, Yip S, Spence JD, Buck B, Verreault S, Casaubon LK, Penn A, Selchen D, Jin A,
Howse D, Mehdiratta M, Boyle K, Aviv R, Kapral MK, Mamdani M; EMBRACE
Investigators and Coordinators. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014 Jun 26;370(26):2467-77. [Barber PA collaborator]
76. Bhatia R, Shobha N, Menon BK, Bal BP, Kochar P, Palumbo V, Wong JH, Morrish WF, Hudon ME, Hu W, Coutts SB, Barber PA, Watson T, Goyal M, Demchuk AM, Hill MD.
Combined full-dose IV and endovascular thrombolysis in acute ischemic stroke. Int J
Stroke 2014 Dec;9(8):974-9. (PMID: 23013039)
77. Coutts SB, Dubuc V, Mandzia J, Kenney C, Demchuk AM, Smith EE, Subramaniam S, Goyal M, Patil S, Menon BK, Barber PA, Dowlatshahi D, Field T, Asdaghi N, Camden
MC, Hill MD; TEMPO-1 Investigators. Tenecteplase-tisssue-type plasminogen activator
evaluation for minor ischemic stroke with proven occlusion. Stroke 2015 Mar 03;46(3):769-
74. (PMID: 25677596)
78. Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, M. Thornton J, Roy D, Jovin TG, Willinsky RA, Sapkota BL, Dowlatshahi D, Frei D, Kamal NR, Montanera WJ, Poppe
AY, Ryckborst KJ, Silver FL, Shuaib A, Tampieri D, Williams D, Bang OY, Baxter BW,
Burns PA, Choe H, Heo JH, Holmstedt CA, Jankowitz B, Kelly M, Linares G, Mandzia JL,
Shankar J, Sohn SI, Swartz RH, Barber PA, Coutts SB, Smith EE, Morrish WF, Weill A,
Subramaniam S, Mitha AP, Wong JH, Mark Lowerison MW, Sajobi TT, Hill MD;
ESCAPE Trial Investigators. Randomized assessment of rapid endovascular treatment of
ischemic stroke. N Engl J Med. 2015 Mar 12;372(11):1019-30. (PMID: 25671798)
79. Demchuk AM, Goyal M, Menon BK, Eesa M, Ryckborst KJ, Kamal N, Patil S, Mishra S, Almekhlafi M, Randhawa PA, Roy D, Willinsky R, Montanera W, Silver FL, Shuaib A,
Rempel J, Jovin T, Frei D, Sapkota B, Thornton JM, Poppe A, Tampieri D, Lum C, Weill
A, Sajobi TT, Hill MD; ESCAPE Trial Investigators. Endovascular treatment for Small
Core and Anterior circulation Proximal occlusion with Emphasis on minimizing CT to
recanalization times (ESCAPE) trial: methodology. Int J Stroke. 2015 Apr;10(3):429-38.
doi: 10.1111/ijs.12424. Epub 2014 Dec 25.
80. Gladstone DJ, Dorian P, Spring M, Panzov V, Mamdani M, Healey JS, Thorpe KE; EMBRACE Steering Committee and Investigators; EMBRACE Steering Committee or
Operations Committee. Atrial Premature Beats Predict Atrial Fibrillation in Cryptogenic
Stroke: Results From the EMBRACE Trial. Stroke 2015 Apr;46(4):936-41. PMID:
25700289 [*Barber PA collaborator]
http://www.ncbi.nlm.nih.gov/pubmed/?term=Demchuk%20AM%5BAuthor%5D&cauthor=true&cauthor_uid=25546514http://www.ncbi.nlm.nih.gov/pubmed/?term=Goyal%20M%5BAuthor%5D&cauthor=true&cauthor_uid=25546514http://www.ncbi.nlm.nih.gov/pubmed/?term=Menon%20BK%5BAuthor%5D&cauthor=true&cauthor_uid=25546514http://www.ncbi.nlm.nih.gov/pubmed/?term=Eesa%20M%5BAuthor%5D&cauthor=true&cauthor_uid=25546514http://www.ncbi.nlm.nih.gov/pubmed/?term=Ryckborst%20KJ%5BAuthor%5D&cauthor=true&cauthor_uid=25546514http://www.ncbi.nlm.nih.gov/pubmed/?term=Kamal%20N%5BAuthor%5D&cauthor=true&cauthor_uid=25546514http://www.ncbi.nlm.nih.gov/pubmed/?term=Patil%20S%5BAuthor%5D&cauthor=true&cauthor_uid=25546514http://www.ncbi.nlm.nih.gov/pubmed/?term=Mishra%20S%5BAuthor%5D&cauthor=true&cauthor_uid=25546514http://www.ncbi.nlm.nih.gov/pubmed/?term=Almekhlafi%20M%5BAuthor%5D&cauthor=true&cauthor_uid=25546514http://www.ncbi.nlm.nih.gov/pubmed/?term=Randhawa%20PA%5BAuthor%5D&cauthor=true&cauthor_uid=25546514http://www.ncbi.nlm.nih.gov/pubmed/?term=Roy%20D%5BAuthor%5D&cauthor=true&cauthor_uid=25546514http://www.ncbi.nlm.nih.gov/pubmed/?term=Willinsky%20R%5BAuthor%5D&cauthor=true&cauthor_uid=25546514http://www.ncbi.nlm.nih.gov/pubmed/?term=Montanera%20W%5BAuthor%5D&cauthor=true&cauthor_uid=25546514http://www.ncbi.nlm.nih.gov/pubmed/?term=Silver%20FL%5BAuthor%5D&cauthor=true&cauthor_uid=25546514http://www.ncbi.nlm.nih.gov/pubmed/?term=Shuaib%20A%5BAuthor%5D&cauthor=true&cauthor_uid=25546514http://www.ncbi.nlm.nih.gov/pubmed/?term=Rempel%20J%5BAuthor%5D&cauthor=true&cauthor_uid=25546514http://www.ncbi.nlm.nih.gov/pubmed/?term=Jovin%20T%5BAuthor%5D&cauthor=true&cauthor_uid=25546514http://www.ncbi.nlm.nih.gov/pubmed/?term=Frei%20D%5BAuthor%5D&cauthor=true&cauthor_uid=25546514http://www.ncbi.nlm.nih.gov/pubmed/?term=Sapkota%20B%5BAuthor%5D&cauthor=true&cauthor_uid=25546514http://www.ncbi.nlm.nih.gov/pubmed/?term=Thornton%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=25546514http://www.ncbi.nlm.nih.gov/pubmed/?term=Poppe%20A%5BAuthor%5D&cauthor=true&cauthor_uid=25546514http://www.ncbi.nlm.nih.gov/pubmed/?term=Tampieri%20D%5BAuthor%5D&cauthor=true&cauthor_uid=25546514http://www.ncbi.nlm.nih.gov/pubmed/?term=Lum%20C%5BAuthor%5D&cauthor=true&cauthor_uid=25546514http://www.ncbi.nlm.nih.gov/pubmed/?term=Weill%20A%5BAuthor%5D&cauthor=true&cauthor_uid=25546514http://www.ncbi.nlm.nih.gov/pubmed/?term=Weill%20A%5BAuthor%5D&cauthor=true&cauthor_uid=25546514http://www.ncbi.nlm.nih.gov/pubmed/?term=Sajobi%20TT%5BAuthor%5D&cauthor=true&cauthor_uid=25546514http://www.ncbi.nlm.nih.gov/pubmed/?term=Hill%20MD%5BAuthor%5D&cauthor=true&cauthor_uid=25546514http://www.ncbi.nlm.nih.gov/pubmed/?term=ESCAPE%20Trial%20Investigators%5BCorporate%20Author%5Dhttp://www.ncbi.nlm.nih.gov/pubmed/25546514
Revised: 2017/11/29 28
81. Cechmanek B, Tuor UI, Rushforth D, Barber PA. Very mild hypothermia (35°C) post-ischemia reduces infarct volume and blood/brain barrier breakdown following tPA
treatment in the mouse. Ther Hypothermia Temp Manag. 2015 Dec 03;5(4):203-8. (PMID:
26075540)
82. Ryan NS, Biessels GJ, Kim L, Nicholas JM, Barber PA, Walsh P, Gami P, Morris HR, Bastos-Leite AJ, Schott JM, Beck J, Mead S, Chavez-Gutierrez L, de Strooper B, Rossor
MN, Revesz T, Lashley T, Fox NC. Genetic determinants of white matter hyperintensities
and amyloid angiopathy in familial Alzheimer’s disease. Neurobiol Aging. 2015 Dec
03;36(12):3140-51. (PMID: 26410308)
83. Au K, Appireddy, R, Barber PA. Multifocal cerebral and bilateral middle cerebellar peduncle infarctions in CADASIL. Can J Neurol Sci. 2016 Jul; 43(4):574-5 (PMID:
26956688)
84. Kosior RK, Tuor UI, Barber PA. Magnetic Resonance Imaging of the Ischemic Core: Systematic Evaluation of Preclinical and Human Data. J Cerebr Blood F Met 2015.
85. Mandzia JL, Smith EE, Horton M, Hanly P, Barber PA, Godzwon C, Donaldson E, Asdaghi N, Patel S, Coutts SB. Imaging and Baseline Predictors of Cognitive Performance
in Minor Ischemic Stroke and patients with transient ischemic attack at 90 days. Stroke.
2016 Mar;47(3):726-31. (PMID: 26846862)
86. Al-Ajlan FS, Goyal M, Demchuk A, Minhas P, Sabiq F, Assis Z, Willinsky R, Montanera W, Rempel J, Shuaib A, Thornton J, Williams D, Roy D, Poppe A, Jovin T, Sapkota B,
Baxter B, Krings T, Silver F, Frei D, Fanale C, Tampieri D, Teitelbaum J, Lum C,
Dowlatshahi D, Shankar J, Barber PA, Hill M, and Menon B, ESCAPE Trial Investigators.
Intra-arterial therapy and Post-Treatment Infarct Volumes: Insights from the ESCAPE
Randomized Controlled Trial. Stroke 2016 Mar;47(3):777-81. (PMID: 26892284)
87. Ganesh A, Al-Ajlan F, Sabiq F, Assis Z, Rempel JL, Butcher K, Thornton J, Kelly P, Roy D, Poppe AY, Jovin TG, Devlin T, Baxter BW, Krings T, Casaubon LK, Frei DF, Choe H,
Tampieri D, Teitelbaum J, Lum C, Mandzia J, Phillips SJ, Bang OY, Almekhlafi MA,
Coutts SB, Barber PA, Sajobi T, Demchuk AM, Eesa M, Hill MD, Goyal M, and Menon
BK; ESCAPE Trial Investigators. Infarct in a New Territory after Treatment Administration
in the ESCAPE Randomized Controlled Trial (Endovascular Treatment for Small Core and
Anterior Circulation Proximal Occlusion with Emphasis on Minimizing CT to
Recanalization Times). Stroke 2016 Dec 03;47(12):2993-2998. (PMID: 27834743)
88. d'Esterre CD, Trivedi A, Pordeli P, Boesen M, Patil S, Ahn SH, Najm M, Fainardi E, Shankar JJS, Rubiera M, Almekhlafi MA, Mandzia J, Khaw AV, Barber P, Coutts S, Hill
MD, Demchuk AM, Sajobi T, Forkert ND, Goyal M, Lee T-Y, and Menon BK. Regional
Comparison of Multi-phase Computed Tomographic Angiography and Computed
Tomographic Perfusion for Prediction of Tissue Fate in Ischemic Stroke. Stroke 2017 Apr
03;48(4);939-945. (PMID 28292870)
Revised: 2017/11/29 29
89. Smith EE, Cieslak A, Barber P, Chen J, Chen YW, Donnini I, Edwards JD, Elbayoumi H, Frayne R, Field TS, Hagedus J, Hanganu V, Ismail Z, Kanji J, Nakajima M, Noor R, Peca
S, Sahlas D, Sharma M, Sposato L, Swartz RH, Zerna C, Black S, Hachinski V.
Therapeutic Strategies and Drug Development for Vascular Cognitive Impairment. J Am
Heart Assoc 2017 May 5;6(5):1-12. (PMID: 28476873)
90. Tariq S, Barber PA. Dementia Risk and Prevention by Targeting Modifiable Vascular Risk Factors. J Neurochem 2017 Jul 22 (PMID: 28734089)
91. Sheikh F, Ismail Z, Mortb, ME, Barber P, Cieslak A, Fischer K, Granger R, Hogan D B, Mackie A, Maxwell CJ, Menon B, Mueller P, Patry D, Pearson D, Quickfall J, Sajobi T,
Tse E, Wang M and Smith EE, for the PROMPT registry investigators. Prevalence of mild
behavioral impairment in mild cognitive impairment and subjective cognitive decline, and
its association with caregiver burden. International Psychogeriatrics (2017 Sept)
Cambridge University Press, pp. 1–12. (PMID 28879833)
92. Sah RG, d’Esterre CD, Hill MD, Hafeez M, Tariq S, Forkert ND, Demchuk AM, Goyal M, Barber PA. Diffusion-Weighted MRI Stroke Volume Following Recanalization Treatment
is Threshold-Dependent. Clin Neuroradiol 2017 Oct 19. (PMID: 29051996)
93. Sah RG, d’Esterrre C, Hill M, Hafeez M, Tariq S, Forkert ND, Frayne R, Demchuk A, Goyal M, Barber P. Early DWI Infarct Growth Occurs Despite Reperfusion in Acute
Ischemic Stroke: Implications for Neuroprotective Trials. Stroke 2017 (Under Revision)
94. Sah RG, Khan S, Forkert ND, Hafeez M, Tariq S, Tsang A, d’Esterre CD, Barber PA. Assessing the lesion heterogeneity using MR diffusion-weighted and quantitative T2
imaging. Stroke 2017 (Submitted)
95. Reid M, Famuyide A, Sah RG, Evans J, Hafeez M, Najm M, Menon B, Demchuk A, Goyal M, d’Esterre C, Barber PA. Can mCTA parenchymal enhancement and mCTA collateral
score improve the selection of patients for endovascular therapy? Stroke 2017 (Submitted)
96. Hill M, Baxter, Krings, Silver, Frei, Fanale, Tampieri, Teitelbaum, Iancu, Shankar, Barber P, Demchuk A, Goyal M, and Menon B. Time for a time window extension: insights from
late presenters in the ESCAPE trial. AJNR (Accepted – due to be published in Jan 2018)
97. Munir, AM, Ursenbach J, Wang M, Zamboni G, Griffanti L, Sah RG, Tariq S, Smith EE, Frayne R, Sajobi TT, Coutts SB, Barber P. Longitudinal Brain Atrophy Rates in Transient
Ischemic Attack and Minor Ischemic Stroke Patients and Cognitive Profiles. IJS 2017
(Submitted)
Non peer reviewed publications (reviews, book chapters)
1. Hill MD, Barber PA, Demchuk AM, Buchan AM. Time is brain: post marketing experience with Alteplase (tPA) for acute ischemic stroke. Today’s Therapeutic Trends18 (4);285-305,
2000.
Revised: 2017/11/29 30
2. Barber PA, Demchuk AM, Hirt L, Buchan AM. The Biochemistry of Ischemic Stroke. Advances in Neurology: Ischemia Stroke, Vol 92, February 2003 Chapter 18:151-164;
Publisher – Lippincott Williams & Wilkins).
3. Barber PA, Bruederlin B, Buchan AM. Experimental neuroprotection: translation to human stroke trials. Maturation Phenomenon in Cerebral Ischemia V, 2004:137-156
4. Pillai, SN, Barber PA. Thrombolysis for Acute Ischemic Stroke in the Elderly- a Review. Geriatrics and Aging 2006
5. Barber PA Neuroprotective Approaches for the Ischemic Cascade: A Good Hiding to Nothing? Stroke Rounds April 2008 (Part 1)
6. Barber PA, Inflammatory Mediators and Dysfunction of the Neurovascular Unit following Ischaemia Reperfusion. In: Neuroinflammation and CNS Disorders published by Wiley
Blackwell 2014 April 01.
Revised: 2017/11/29 31
ABSTRACTS – published
1. Barber PA, Varma AR, Lloyd JJ, Haworth B, Snowden JS, Neary D. The
electroencephalogram in dementia with Lewy bodies. Journal of Neurology Neurosurgery,
and Psychiatry supplement 1999; 67:267
2. Barber PA, Klein GM, Hudon M, Hu W, Newcommon NJ, Buchan AM. Intra-arterial
thrombolysis in five patients with basilar artery thrombosis. Canadian Journal of
Neurological Science 1999; 26; Suppl.1 S10
3. Barber PA, Newcommon, Zhang J, Karbalai H, Buchan AM. Thrombolytic treatment in
acute stroke: the Calgary experience. Canadian Journal of Neurological Science 1999; 26;
suppl.1-S26
4. Barber PA, Zhang J, Hu W, Newcommon, Buchan AM. The interobserver reliability of the
Alberta Stroke Program CT Scoring System. Canadian Journal of Neurological Science
1999; 26; suppl.1-S63
5. Barber PA, Demchuk AM, Zhang J, Grotta JC, Buchan AM. The use and validity of a
quantitative CTscore in acute hemispheric stroke in predicting outcome prior to thrombolytic
treatment. Journal of Neurology, Neurosurgery and Psychiatry 2000; 68:261
6. Barber PA, Zhang J, Buchan AM. Use and validity of a quantitative score in early cerebral
ischemia. Annals of Neurology 1999
7. Barber PA, Demchuk AM, Zhang J, Sevick R, Hu W, Hudon M, Scott J, KuaraD, Grotta
JC, Buchan AM. The validity and reliability of a novel quantitative CT Score in predicting
outcome prior to thrombolytic treatment. Stroke 2000; 31:275
8. Hill MD, Barber PA, Buchan AM. Canadian Activase Stroke Effectiveness Study. Stroke
2000; 31:315
9. Demchuk AM, Christou I, Felberg RA, Barber PA, Malkoff M, Alexandrov AV.
Thrombolysis in Brain Ischemia (TIBI) flow grades predict likelihood of recanalization and
recovery in intravenous tPA treated patients. Stroke 2000; 31:275
10. Demchuk AM, Felberg RA, Christou I, Wein TH, Barber PA, Malkoff M, Grotta JC.
Combined intravenous and intra-arterial thrombolytic therapy for severe stroke. Stroke 2000;
31:283. (platform)
11. Alexandrov AV, Demchuk AM, Felberg RA, Christou I, Barber PA, Burgin S, Malkoff M,
Wojner AW, Grotta JC. Dramatic improvement during intravenous tPA infusion combined
with 2 MHz TCD monitoring is associated with early recanalization. Stroke 2000; 31:284.
(platform)
Revised: 2017/11/29 32
12. Frayne R, Sevick RJ, Demchuk AM, Barber PA, Hill MD, Cole Haskayne, Curtis S,
Buchan AM. Acute stroke imaging at 3T. Proc. Intl. Soc. Mag. Reson. Med. 8 (2000).
(Poster)
13. Teal P, Hill MD, Buchan AM for the CASES Study Group. Canadian Activase for Stroke
Effectiveness Study (CASES). Neurology 2000; 54(suppl 3); A390. (Presented at AAN
Meeting San Diego, April 2000) (platform)
14. Barber PA, Demchuk AM, Hudon ME, Pexman W, Hill MD, Zhang, Buchan AM. The
hyperdense sylvian fissure branch sign: a marker of thromboembolic stroke. Canadian
Journal of Neuroscience 2000; 27: S24. (platform)
15. Barber PA, Zhang J, Demchuk, Hill MD, Cole Haskayne A, Newcommon N, Buchan AM.
An analysis of patient eligibility for alteplase in acute ischemic stroke. Canadian Journal of
Neuroscience 2000; 27:S25
16. Canadian Activase Stroke Effectiveness Study (CASES). Canadian Journal of
Neurosciences 2000; 27:S25
17. Buchan AM, Hill MD for the CASES Investigators. The Canadian Activase for Stroke
Effectiveness Study (CASES). Cerebrovasc Dis 2000; 10(Suppl 2):81. (Presented at
European Stroke Meeting, Vienna 2000)
18. Barber PA, Zhang J, Demchuk AM, Hill MD, Cole-Haskayne A, Newcommon N, Virji H,
Buchan AM. Why don’t stroke patients receive alteplase? An analysis of patient eligibility:
implications for improving clinical impact by increasing patient numbers. Ann Neurol
(suppl) 2000
19. Phillip S, Gubitz G, Hill MD, Buchan AM for the CASES Investigators. The Canadian
Activase for Stroke Effectiveness Study (CASES). Ann Neurol (suppl) 2000
20. Barber PA, Demchuk AM, Hudon ME, Pexman W, Hill MD, Zhang, Buchan AM. The
hyperdense sylvian fissure branch sign: a marker of thromboembolic stroke. (World
Congress of Stroke, Melbourne Australia)
21. Demchuk AM, Burgin WS, Felberg RA, Christou I, Barber PA, Hill MD, Beaupre D,
Alexandrov AV. TCD TIBI Classification Correlates with Clinical Severity, Flow Recovery
and Short Term Outcome in Intravenous TPA Treated Stroke Patients. (World Congress of
Stroke, Melbourne Australia)
22. Hill MD, Barber PA, Demchuk AM, Pexman JPW, Buchan AM, for the CASES
Investigators. Baseline ASPECT scores predict extent of stroke: interim CT analysis of
CASES. Stroke 2001; 32: 319
Revised: 2017/11/29 33
23. Barber PA, Demchuk AM, Hill MD, Pexman W, Hudon ME, Tomanek A, Beaupre
D,Frayne R, Buchan AM. A comparison of CT versus MR imaging in acute stroke using
ASPECTS: Will the “new” replace the “old” as the preferred imaging modality? Stroke
2001; 32:325
24. Barber PA, Zhang J, Kasner S, Krieger D, Demchuk AM. The Role of Repeat CT for
predicting fatal outcome following massive middle cerebral artery territory infarction. Stroke
2001; 32:346
25. Barber PA, Zhang J, Demchuk AM, Hill MD, Cole Haskayne A, Newcommon N, Virji H,
Buchan AM. Why stroke patients don’t receive t-PA? An analysis of patient eligibility:
implications for improving clinical impact by increasing future treatment numbers. Stroke
2001; 32:372
26. Barber PA, Zhang J, Kasner S, Krieger D, Demchuk AM. The Role of Repeat CT for
predicting fatal outcome following massive middle cerebral artery territory infarction. Stroke
2001; 32:381
27. Demchuk AM, Hill MD, Buchan AM, CASES Study Group. The Canadian Activase for
Stroke Effectiveness Study (CASES). Stroke 2000; 31:315. (Poster)
28. Hill MD, Newcommon N, Barber PA, Demchuk AM, Cole-Haskayne A, Buchan AM.
Intra-arterial therapy following intravenous alteplase for acute ischemic stroke. Stroke 2001;
32: 382
29. Demchuk AM, Beaupre D, Barber PA, Hill MD, Button A, Morrish W, Hudon M. A stroke
neurologist/nurse TCD operated acute stroke service can reliably identify MCA occlusion
when compared to MRA. Stroke 2001; 32:246
30. Burgin WS, Wojner AW, Demchuk AM, Felberg RA, Barber PA, Hill MD, Malkoff M, El-
Mitwalli A, Piyawat P, Newcommon N, Button A. Validity and Reliability of the
Thrombolysis in Brain Infarction (TIBI) Flow Grades. Stroke 2001; 32:324
31. Hill MD, Buchan AM for the CASES Investigators. The Canadian Activase for Stroke
Effectiveness Study (CASES): Interim results. Stroke 2001; 32: 337
32. Frayne R, Sevick RJ, Hudon M, Morrish W, Demchuk AM, Barber PA, Hill MD, Buchan
AM. Intracranial TOF in Hyper-acute Stroke. XII International Workshop on Magnetic
Resonance Angiography, Lyon, France. (platform)
33. Ryder RC, Cole-Haskayne A, Sevick R, Demchuk A, Hill M, Barber P, Buchan A, Frayne
R. Cerebral Blood Volume: Possible Predictor of Clinical Deficit in Acute Stroke. Proc
ISMRM
Revised: 2017/11/29 34
34. Barber PA, Hill MD, Demchuk AM, Pexman W, Hudon ME, Buchan AM. A comparison
of CT versus MR Imaging in Hyperacute Stroke using a Topographical Quantitative Scoring
System (ASPECTS). Neurology 2001; 56:A260
35. Sevick RJ, Frayne R, Demchuk AM, Barber PA, Hill MD, Buchan AM. Evaluation of
acute stroke with high field MR. RSNA 2000, 86th Scientific Assembly and Annual
Meeting, Chicago, Illinois, 2000
36. Frayne R, Sevick RJ, Hudon M, Morrish W, Demchuk AM, Barber PA, Hill MD, Buchan
AM "Intracranial TOF in Hyper-Acute Stroke" Proceedings of XII International Workshop
on Magnetic Resonance Angiography, Canadian Cardiovascular Meeting, Vancouver, BC,
2000
37. Demchuk AM, Hill MD, Buchan AM, and the CASES Investigators. The Canadian
Activase for Stroke Effectiveness Study
38. Ryder RC, Cole-Haskayne A, Sevick RJ, Demchuk AM, Hill MD, Barber PA,
Newcommon NJ, Buchan AM, Frayne R. Relative Cerebral Blood Volume Changes in
Acute Stroke
39. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Multicentre Experience of
Large Middle Cerebral Artery Infarction: The Role of CT for Predicting Fatal Outcome.
CJNS 2001
40. Tomenek A, Mitchel R, Barber PA, Hill MD, Buchan AM. Serial Multimodal Magnetic
Resonance Imaging Study of Acute Stroke. CJNS 2001
41. Barber PA, Hill MD, Demchuk AM, Pexman W, Hudon ME, Buchan AM. A comparison
of CT versus Diffusion Weighted Imaging in Hyperacute Stroke Using a Topographical
Quantitative Scoring System (ASPECTS). JNNP 2001
42. Hill MD, Lye T, Moss H, Barber PA, Newcommon N, Green T, Kenney C, Cole- Haskayne
A, Buchan AM. Hemi-orolingual Angioedema After Alteplase Treatment of Stroke is
Associated with Angiotensin Converting Enzyme Inhibitor Use. Stroke 33 2002
43. Hill MD, Barber PA, Demchuk AM, Buchan AM, Pexman W, Hu W, Hudon M, Morrish
W, Schebel M, Gray S, Resenowsky L. Validation of the ASPECT Score as a predictor of
outcome: Analysis of the ATLANTIS–B Study. Stroke 33 2002
44. Hill MD, Buchan AM and the CASES Investigators. The Canadian Activase for Stroke
Effectiveness Study (CASES): Final Results. Stroke 33 2002
Revised: 2017/11/29 35
45. Barber PA, Demchuk AM, Hill MD, Pexman JHW, Hudon M and Buchan AM for the
ASPECTS Study Group. What is the Significance of the Hyperdense Middle Cerebral
Artery and Sylvian Fissure “Dot” Sign in Acute Stroke Care? A CT study with Magnetic
Resonance Angiography correlation. Stroke 33 2002
46. Demchuk AM, Schebel M, Beaupre D, Buchan AM, Frayne R, Morr